Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Boston Scientific Scimed Inc | 24 |
| 2 | GE Healthcare AS | 24 |
| 3 | Entero Therapeutics Inc | 17 |
| 4 | Boston Scientific Corp | 15 |
| 5 | Hyperbranch Medical Technology Inc | 15 |
| 6 | Aquestive Therapeutics Inc | 13 |
| 7 | Cornell University | 13 |
| 8 | Institut National de la Santé et de la Recherche Médicale | 12 |
| 9 | Boston Scientific Ltd Barbados | 10 |
| 10 | University of Alabama at Birmingham UAB | 10 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 384 |
| 2 | A61P | Therapeutic activity (drug indications) | 234 |
| 3 | A61L | Sterilising / disinfecting materials | 130 |
| 4 | C08L | Polymer compositions (blends) | 106 |
| 5 | A61B | 53 |
| 6 | A61F | 46 | |
| 7 | C07C | Acyclic and carbocyclic compounds | 39 |
| 8 | C07K | Peptides | 36 |
| 9 | C07D | Heterocyclic compounds | 31 |
| 10 | C08F | Polymers from C=C unsaturated bonds | 30 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Traumatic Brain Injury and Neurovascular Disturbances | 2 |
| 2 | Advanced X-ray and CT Imaging | 1 |
| 3 | Barrier Structure and Function Studies | 1 |
| 4 | Pediatric Urology and Nephrology Studies | 1 |
| 5 | Venous Thromboembolism Diagnosis and Management | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Amosov Is | 3 | |
| 2 | A. Basil Harris | 2 | |
| 3 | Alex Chan | University of Tennessee at Knoxville | 2 |
| 4 | Arthur E. Rosenbaum | Pittsburg State University | 2 |
| 5 | B. E. Kendall | University College London | 2 |
| 6 | CW Kerber | 2 | |
| 7 | Erich G. Krueger | Eastern Research Group (United States) | 2 |
| 8 | Ganichkin Am | 2 | |
| 9 | Glenn E. Jones | University of Rochester | 2 |
| 10 | Herbert J. Glatt | University of Tennessee at Knoxville | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Neurotoxicity of radiological contrast agents | 1983 | 242 | Traumatic Brain Injury and Neurovascular Disturbances |
| Fish under exercise | 2011 | 181 | Aquaculture Nutrition and Growth |
| Extradural block. Confirmation of the injection site by X‐ray monitoring | 1985 | 163 | Anesthesia and Pain Management |
| Modification of cyanoacrylate for therapeutic embolization: preliminary experience | 1979 | 119 | Trauma Management and Diagnosis |
| Long-Term Outcome of Embolotherapy and Surgery for High-Flow Extremity Arteriovenous Malformations | 2000 | 116 | Vascular Malformations and Hemangiomas |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular weight of Myodil?
Which organizations hold the most patents related to Myodil?
What are the primary patent classifications associated with Myodil?
What research topics are associated with published papers on Myodil?
How has the patent activity for Myodil trended in recent years?